This blog is part of our Month of CIRM series, which features our Agency’s progress towards achieving our mission to accelerate stem cell treatments to patients with unmet medical needs.
This week, we’re highlighting CIRM-funded clinical trials to address the growing interest in our rapidly expanding clinical portfolio. Today we are featuring trials in our blood and immune disorders portfolio, specifically focusing on sickle cell disease, HIV/AIDS, severe combined immunodeficiency (SCID, also known as bubble baby disease) and rare disease called chronic granulomatous disease (CGD).
CIRM has funded a total of eight trials targeting these disease areas, all of which are currently active. Check out the infographic below for a list of those trials.
For more details about all CIRM-funded clinical trials, visit our clinical trials page and read our clinical trials brochure which provides brief overviews of each trial.
The Stem Cellar 
CIRM-funded clinical trials represent a significant advancement in treating blood and immune disorders, utilizing innovative approaches, including peptides. These small chains of amino acids can play a crucial role in modulating immune responses and enhancing therapeutic efficacy. Trials targeting conditions like sickle cell disease and SCID are particularly promising, as they explore how peptides can improve patient outcomes. By focusing on these cutting-edge treatments, CIRM is paving the way for breakthroughs that could transform the lives of those with unmet medical needs.